Biorhythm-mimicking growth hormone patch
Source abstract
Abstract
Timing dosing throughout the day impacts the therapeutic efficacy and side effects of medications. Thus, optimizing release profiles to synchronize drug concentrations with natural rhythms is critical for optimal therapeutic benefits. However, existing delivery systems are still inefficient in delivering drugs in a biorhythm-mimicking fashion. Here we describe a biorhythm-inspired growth hormone transdermal microneedle patch with multistage drug release that mimics the natural rhythm of human growth hormone secretion at night. Programmed drug release is achieved by combining a 'burst-release' module with several 'delayed-release' modules. Compared with the subcutaneous daily injections currently used in clinics, the patch exhibits enhanced efficacy in terms of longitudinal bone growth and bone quality, leading to bone length increases of ~10 mm and ~5 mm in healthy rats and growth hormone gene knockout mice, respectively. Our findings reveal that the biorhythm-mimicking release pattern significantly enhances growth hormone bioavailability and effectively regulates the growth-related biological process, thus boosting the secretion of insulin-like growth factor-1 and ultimately promoting bone growth.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Exercise and Physiological Responses · Advancements in Transdermal Drug Delivery · Adipose Tissue and Metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (48)
Show source-provided references
1. Montaruli, A. et al. Biological rhythm and chronotype: new perspectives in health. Biomolecules 11, 487 (2021).10.3390/biom11040487 ↗
2. Benca, R. et al. Biological rhythms, higher brain function, and behavior: gaps, opportunities, and challenges. Brain Res. Rev. 62, 57–70 (2009).10.1016/j.brainresrev.2009.09.005 ↗
3. Chaput, J.-P. et al. The role of insufficient sleep and circadian misalignment in obesity. Nat. Rev. Endocrinol. 19, 82–97 (2023).10.1038/s41574-022-00747-7 ↗
4. Wei, Y. et al. A novel sustained-release formulation of recombinant human growth hormone and its pharmacokinetic, pharmacodynamic and safety profiles. Mol. Pharm. 9, 2039–2048 (2012).10.1021/mp300126t ↗
5. Cotterill, A. M., Holly, J. M. P., Snodgrass, G. A. I. & Savage, M. O. Regulation of growth hormone secretion in patients with growth hormone insensitivity. Acta Paediatr. 80, 92–95 (1991).10.1111/apa.1991.80.s377.92 ↗
6. Liao, S. et al. Comparison of pulsatile vs. continuous administration of human placental growth hormone in female C57BL/6J mice. Endocrine 54, 169–181 (2016).10.1007/s12020-016-1060-0 ↗
7. Hindmarsh, P. C., Matthews, D. R. & Brook, C. G. D. Growth hormone secretion in children determined by time series analysis. Clin. Endocrinol. 29, 35–44 (1988).10.1111/j.1365-2265.1988.tb00247.x ↗
8. Mauras, N. et al. Augmentation of growth hormone secretion during puberty: evidence for a pulse amplitude-modulated phenomenon. J. Clin. Endocr. Metab. 64, 596–601 (1987).10.1210/jcem-64-3-596 ↗
9. Lee, J. W., Choi, S.-O., Felner, E. I. & Prausnitz, M. R. Dissolving microneedle patch for transdermal delivery of human growth hormone. Small 7, 531–539 (2011).10.1002/smll.201001091 ↗
10. Yang, L. et al. Actively separated microneedle patch for sustained-release of growth hormone to treat growth hormone deficiency. Acta Pharm. Sin. B 13, 344–358 (2023).10.1016/j.apsb.2022.04.015 ↗
11. Yu, J. et al. Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs. Nat. Biomed. Eng. 4, 499–506 (2020).10.1038/s41551-019-0508-y ↗
12. Chen, Z. et al. Bioorthogonal catalytic patch. Nat. Nanotechnol. 16, 933–941 (2021).10.1038/s41565-021-00910-7 ↗
13. Wang, Z. et al. Dual self-regulated delivery of insulin and glucagon by a hybrid patch. Proc. Natl Acad. Sci. USA 117, 29512–29517 (2020).10.1073/pnas.2011099117 ↗
14. Chen, B. Z., Zhang, L. Q., Xia, Y. Y., Zhang, X. P. & Guo, X. D. A basal-bolus insulin regimen integrated microneedle patch for intraday postprandial glucose control. Sci. Adv. 6, eaba7260 (2020).10.1126/sciadv.aba7260 ↗
15. Li, W. et al. Rapidly separable microneedle patch for the sustained release of a contraceptive. Nat. Biomed. Eng. 3, 220–229 (2019).10.1038/s41551-018-0337-4 ↗
16. Prausnitz, M. R. & Langer, R. Transdermal drug delivery. Nat. Biotechnol. 26, 1261–1268 (2008).10.1038/nbt.1504 ↗
17. Yang, C. et al. Glucose-responsive microneedle patch for closed-loop dual-hormone delivery in mice and pigs. Sci. Adv. 8, eadd3197 (2022).10.1126/sciadv.add3197 ↗
18. Tran, K. T. M. et al. Transdermal microneedles for the programmable burst release of multiple vaccine payloads. Nat. Biomed. Eng. 5, 998–1007 (2021).10.1038/s41551-020-00650-4 ↗
19. Drube, J. et al. Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. Nat. Rev. Nephrol. 15, 577–589 (2019).10.1038/s41581-019-0161-4 ↗
20. Chaiya, P., Rojviriya, C., Pichayakorn, W. & Phaechamud, T. New insight into the impact of effervescence on gel layer microstructure and drug release of effervescent matrices using combined mechanical and imaging characterisation techniques. Pharmaceutics 14, 2299 (2022).10.3390/pharmaceutics14112299 ↗
21. Krögel, I. & Bodmeier, R. Floating or pulsatile drug delivery systems based on coated effervescent cores. Int. J. Pharm. 187, 175–184 (1999).10.1016/S0378-5173(99)00189-1 ↗
22. Yadav, D., Survase, S. & Kumar, N. Dual coating of swellable and rupturable polymers on glipizide loaded MCC pellets for pulsatile delivery: formulation design and in vitro evaluation. Int. J. Pharm. 419, 121–130 (2011).10.1016/j.ijpharm.2011.07.026 ↗
23. Lui, J. C. et al. Cartilage-targeted IGF-1 treatment to promote longitudinal bone growth. Mol. Ther. 27, 673–680 (2019).10.1016/j.ymthe.2019.01.017 ↗
24. Clark, R. G., Carlsson, L. M. S. & Robinson, I. C. A. F. Growth hormone secretory profiles in conscious female rats. J. Endocrinol. 114, 399–407 (1987).10.1677/joe.0.1140399 ↗
25. Nishad, R., Mukhi, D., Menon, R. K. & Pasupulati, A. K. J. D. Growth hormone and metabolic homeostasis. Eur. Med. J. Diabetes 6, 78–87 (2018).
26. Lu, M., Flanagan, J. U., Langley, R. J., Hay, M. P. & Perry, J. K. Targeting growth hormone function: strategies and therapeutic applications. Signal Transduct. Target. Ther. 4, 3 (2019).10.1038/s41392-019-0036-y ↗
27. Moriyama, K. et al. Regulation of osteoclastogenesis through TIM-3: possible involvement of the TIM-3/galectin-9 system in the modulation of inflammatory bone destruction. Lab. Invest. 94, 1200–1211 (2014).10.1038/labinvest.2014.107 ↗
28. Chennaoui, M. et al. Changes of cerebral and/or peripheral adenosine A1 receptor and IGF-I concentrations under extended sleep duration in rats. Int. J. Mol. Sci. 18, 2439 (2017).10.3390/ijms18112439 ↗
29. Chen, P. et al. A natural extracellular matrix hydrogel through selective nutrient restriction for hyperinflammatory starvation therapy. Matter 6, 397–428 (2023).10.1016/j.matt.2022.12.002 ↗
30. Yoon, S.-H., Grynpas, M. D. & Mitchell, J. Growth hormone increases bone toughness and decreases muscle inflammation in glucocorticoid-treated Mdx mice, model of Duchenne muscular dystrophy. J. Bone Miner. Res. 34, 1473–1486 (2019).10.1002/jbmr.3718 ↗
31. Allada, R. & Bass, J. Circadian mechanisms in medicine. N. Engl. J. Med. 384, 550–561 (2021).10.1056/NEJMra1802337 ↗
32. Lane, J. M. et al. Genetics of circadian rhythms and sleep in human health and disease. Nat. Rev. Genet. 24, 4–20 (2023).10.1038/s41576-022-00519-z ↗
33. Ruan, W., Yuan, X. & Eltzschig, H. K. Circadian rhythm as a therapeutic target. Nat. Rev. Drug Discov. 20, 287–307 (2021).10.1038/s41573-020-00109-w ↗
34. Dallmann, R., Brown, S. A. & Gachon, F. Chronopharmacology: new insights and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 54, 339–361 (2014).10.1146/annurev-pharmtox-011613-135923 ↗
35. Cervantes-Silva, M. P. et al. The circadian clock influences T cell responses to vaccination by regulating dendritic cell antigen processing. Nat. Commun. 13, 7217 (2022).10.1038/s41467-022-34897-z ↗
36. Wang, C. et al. Dendritic cells direct circadian anti-tumour immune responses. Nature 614, 136–143 (2023).10.1038/s41586-022-05605-0 ↗
37. Han, J. et al. Bioresponsive immunotherapeutic materials. Adv. Mater. 36, 2209778 (2023).10.1002/adma.202209778 ↗
38. McHugh, K. J. et al. Fabrication of fillable microparticles and other complex 3D microstructures. Science 357, 1138–1142 (2017).10.1126/science.aaf7447 ↗
39. Lu, X. et al. Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy. Sci. Transl. Med. 12, eaaz6606 (2020).10.1126/scitranslmed.aaz6606 ↗
40. Lee, S. H. et al. Implantable multireservoir device with stimulus-responsive membrane for on-demand and pulsatile delivery of growth hormone. Proc. Natl Acad. Sci. USA 116, 11664–11672 (2019).10.1073/pnas.1906931116 ↗
41. Westwood, M. et al. The effect of different patterns of growth hormone administration on the IGF axis and somatic and skeletal growth of the dwarf rat. Amer. J. Physiol. Endocrinol. Metab. 298, E467–E476 (2010).10.1152/ajpendo.00234.2009 ↗
42. Groesbeck, M. D. & Parlow, A. F. Highly improved precision of the hypophysectomized female rat body weight gain bioassay for growth hormone by increased frequency of injections, avoidance of antibody formation, and other simple modifications. Endocrinology 120, 2582–2590 (1987).10.1210/endo-120-6-2582 ↗
43. Spiegel, K. et al. Adaptation of the 24-h growth hormone profile to a state of sleep debt. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, R874–R883 (2000).10.1152/ajpregu.2000.279.3.R874 ↗
44. Hindmarsh, P. C., Fall, C. H. D., Pringle, P. J., Osmond, C. & Brook, C. G. D. Peak and trough growth hormone concentrations have different associations with the insulin-like growth factor axis, body composition, and metabolic parameters. J. Clin. Endocr. Metab. 82, 2172–2176 (1997).
45. Gevers, E. F., Wit, J. M. & Robinson, I. C. Growth, growth hormone (GH)-binding protein, and GH receptors are differentially regulated by peak and trough components of the GH secretory pattern in the rat. Endocrinology 137, 1013–1018 (1996).10.1210/endo.137.3.8603568 ↗
46. Maiter, D., Underwood, L. E., Maes, M., Davenport, M. L. & Ketelslegers, J. M. Different effects of intermittent and continuous growth hormone (GH) administration on serum somatomedin-C/insulin-like growth factor I and liver GH receptors in hypophysectomized rats. Endocrinology 123, 1053–1059 (1988).10.1210/endo-123-2-1053 ↗
47. Challet, E. Keeping circadian time with hormones. Diabetes Obes. Metab. 17, 76–83 (2015).10.1111/dom.12516 ↗
48. Borski, R. J., Tsai, W., Demott-Friberg, R. & Barkan, A. L. Induction of growth hormone (GH) mRNA by pulsatile GH-releasing hormone in rats is pattern specific. Amer. J. Physiol. Endocrinol. Met. 278, E885–E891 (2000).10.1152/ajpendo.2000.278.5.E885 ↗